Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Accrued expenses Total accrued expenses Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Award expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Interest income Interest Income, Other Award Type [Domain] Award Type [Domain] Number of shares, beginning balance (in shares) Number of shares, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Proceeds from the sale of future royalties Proceeds From Sale Of Advance Future Royalties Proceeds From Sale Of Advance Future Royalties Schedule of Available-for-sale Investments Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Number of shares, Restricted stock units expected to vest (in dollars per share) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value Accounts payable Accounts Payable, Current Weighted average remaining contractual term, options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Total other income (expense), net Nonoperating Income (Expense) Anti-PD-1 (Jemperli/Dostarlimab) AnaptysBio-generated Anti-PD-1 (Jemperli/Dostarlimab) [Member] AnaptysBio-generated Anti-PD-1 (Jemperli/Dostarlimab) Shares subject to options, exercisable, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Liabilities Related To Sale Of Future Royalties [Line Items] Liabilities Related To Sale Of Future Royalties [Line Items] Liabilities Related To Sale Of Future Royalties Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] By the end of 2026 First Installment [Member] First Installment Stockholders' Equity Equity [Text Block] Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Issuance of common stock upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Directors Director [Member] Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at September 30, 2023 and December 31, 2022, respectively Preferred Stock, Value, Issued Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Forfeitures and cancellations (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Diluted (in dollars per share) Earnings Per Share, Diluted Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] GSK GlaxoSmithKline [Member] GlaxoSmithKline First MAA approval - first indication First Marketing Authorization Application Approval - First Indication [Member] First Marketing Authorization Application Approval - First Indication Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Stock options outstanding, beginning balance (in shares) Stock options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Non cash share based compensation expense Share-Based Payment Arrangement, Accelerated Cost IND clearance from the FDA Clearance Of Investigational New Drug From FDA [Member] Clearance Of Investigational New Drug From FDA [Member] Trading Symbol Trading Symbol Agency securities US Government Agencies Debt Securities [Member] Monthly base rate (in dollars per sqft) Rent Per Square Foot Rent Per Square Foot Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average grant date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Remaining maturity (in years) Available-for-sale Debt Securities, Remaining Maturity Available-for-sale Debt Securities, Remaining Maturity LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grantsed Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grantsed ESPP Employee Stock [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Royalty Agreement, Above $1.0 billion Royalty Agreement, Above $1. 0 billion [Member] Royalty Agreement, Above $1. 0 billion Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to) Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Number of Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Quoted Market Prices for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Schedule of Property and Equipment, net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Certificates of deposit Certificates of Deposit [Member] Shares reserved for future award grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Filing of the first BLA - second indication Filing of Biologics License Application - Second Indication [Member] Filing of Biologics License Application - Second Indication Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Small Business Entity Small Business Local Phone Number Local Phone Number Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four First BLA approval - first indication First Biologics License Application Approval - dMMREC [Member] First Biologics License Application Approval - dMMREC Measurement Frequency [Axis] Measurement Frequency [Axis] Payment rate Advance Future Royalties, Rate Advance Future Royalties, Rate Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Targets Revenue Recognition, Material Agreement Terms, Targets Revenue Recognition, Material Agreement Terms, Targets Restricted Stock Units RSUs Restricted Stock Units (RSUs) [Member] First MAA approval - second indication First Marketing Authorization Application Approval - Second Indication [Member] First Marketing Authorization Application Approval - Second Indication Payments for debt issuance costs Payments of Debt Issuance Costs Income Statement Location [Axis] Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Schedule of Future Minimum Annual Obligations Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Product and Service [Domain] Product and Service [Domain] Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Costs in Cash Flow Statement Lease, Cost [Table Text Block] Research and development Research and Development Expense [Member] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Award Type [Axis] Award Type [Axis] Options to purchase common stock (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Liabilities Related To Sale Of Future Royalties [Table] Liabilities Related To Sale Of Future Royalties [Table] Liabilities Related To Sale Of Future Royalties Document Quarterly Report Document Quarterly Report Royalties and milestones, agreement amount to be received Advance Future Royalties, Aggregate Additional Payment Advance Future Royalties, Aggregate Additional Payment Amounts accrued for property and equipment Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Number of outstanding research and development targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets General and administrative General and Administrative Expense [Member] Property and equipment, gross Property, Plant and Equipment, Gross Weighted average remaining contractual term, options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Proceeds from sale of future royalties Proceeds From Advance Future Royalties Proceeds From Advance Future Royalties Schedule of Time-based Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Current portion of operating lease liability Operating Lease, Liability, Current Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Royalties Royalty Agreement [Member] Royalty Agreement Sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Average price paid per share (in dollars per share) Shares Acquired, Average Cost Per Share Counterparty Name [Domain] Counterparty Name [Domain] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Sagard Sagard Healthcare Royalty Partners, LP [Member] Sagard Healthcare Royalty Partners, LP Operating lease cost Operating Lease, Cost Weighted-average number of shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] 12 months or greater, Fair value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued (in shares) Common Stock, Shares, Issued Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Schedule of Weighted Average Assumptions used to Estimate Fair Value Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Gross Unrealized Losses Unrealized losses on available-for-sale Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Accrued for repurchases of common stock Accrued Common Stock Repurchased Accrued Common Stock Repurchased Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Collaborative Research and Development Agreements Collaborative Arrangement Disclosure [Text Block] Options to purchase common stock Stock Options Employee Stock Option [Member] Weighted average period remaining for amortization of unrecognized compensation cost (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Award equivalent shares Share-based Compensation Arrangement by Share-based Payment Award, Common Share Equivalent Share-based Compensation Arrangement by Share-based Payment Award, Common Share Equivalent Entity Address, Address Line One Entity Address, Address Line One Approximate dollar value of shares purchased (in dollars per share) Treasury Stock, Value, Acquired, Cost Method Entity Address, Address Line Two Entity Address, Address Line Two Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] CEO Chief Executive Officer [Member] Equity Incentive Plans Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Purchases of investments Payments to Acquire Debt Securities, Available-for-Sale Weighted-Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Proceeds, contingent on annual sales milestones upfront percentage Advance Future Royalties, Aggregate Payment, Threshold Percent Advance Future Royalties, Aggregate Payment, Threshold Percent Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to) Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Receivables from collaborative partners Increase (Decrease) in Contract with Customer, Asset Title of 12(b) Security Title of 12(b) Security Effective royalty rate Advance Future Royalties, Effective Royalty Rate Advance Future Royalties, Effective Royalty Rate Weighted average grant date fair value, beginning balance (in dollars per share) Weighted average grant date fair value, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Class of Stock [Line Items] Class of Stock [Line Items] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Statistical Measurement [Axis] Statistical Measurement [Axis] Net sales royalty Net Sales Royalty Threshold Net Sales Royalty Threshold Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Repurchase and retirements of common stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Milestones that may be recognized in the future Milestones Yet To Be Recognized [Member] Milestones Yet To Be Recognized Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Sale of Future Royalties Sale Of Future Royalties Text Block [Text Block] Sale Of Future Royalties Text Block Security deposit Security Deposit Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Schedule of Non-cash Stock-based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Unrealized gain (loss) on available for sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Lease Agreement 10770 Wateridge Circle, San Diego, California 92121 [Member] 10770 Wateridge Circle, San Diego, California 92121 Agreement term following first commercial sale or expiration of the last to expire patent Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Number of milestones achieved during period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Stockholders' equity, beginning balance (in shares) Stockholders' equity, ending balance (in shares) Shares, Outstanding Number of shares, Restricted stock units expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Common stock, par value (in dollars per share) stock repurchase plan, common stock par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Phase 2 clinical trial initiation Phase 2 Clinical Trial Initiation [Member] Phase 2 Clinical Trial Initiation [Member] Revenue recognition multiple deliverable arrangements upfront fee receivable Revenue Recognition Multiple Deliverable Arrangements Upfront Fees Revenue Recognition Multiple Deliverable Arrangements Upfront Fees Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Shares Subject to Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] GlaxoSmithKline Collaboration Collaborative Arrangement [Member] Name of Property [Domain] Name of Property [Domain] Repurchases and retirements of common stock Stock Repurchased and Retired During Period, Value Lease liability Total Operating Lease, Liability Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position Measurement Frequency [Domain] Measurement Frequency [Domain] Title of Individual [Axis] Title of Individual [Axis] Plan Name [Axis] Plan Name [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Number of reportable segments Number of Reportable Segments Issuance of common stock from exercises of options and employee stock purchase plan Stock Issued During Period, Value, Options and Employee Stock Purchase Plan Stock Issued During Period, Value, Options and Employee Stock Purchase Plan Net loss per common share: Earnings Per Share [Abstract] Open Market Sales Agreement Open Market Sales Agreement [Member] Open Market Sales Agreement Common stock, $0.001 par value, 500,000 shares authorized, 26,575 shares and 28,513 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Less than 12 months, Fair value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Commercial and corporate obligations Commercial And Corporate Obligations [Member] Commercial And Corporate Obligations [Member] Accrued professional fees Accrued Professional Fees, Current Amortization of right-of-use assets – operating Operating Lease, Right-of-Use Asset, Periodic Reduction Total current assets Assets, Current Annual increase in number of shares available for issuance percentage Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Zejula revenue prior to the Zejula Royalty Monetization Agreement Zejula Revenue [Member] Zejula Revenue Revenue from Contract with Customer [Abstract] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Other income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Schedule of Repurchase Activity Class of Treasury Stock [Table Text Block] Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Net Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Authorized repurchase amount Stock Repurchase Program, Authorized Amount Accrued research, development and manufacturing expenses Accrued Research And Development Expenses, Current Accrued Research And Development Expenses, Current First BLA approval - second indication First Biologics License Application Approval - Second Indication [Member] First Biologics License Application Approval - Second Indication Weighted average remaining contractual term, other than options vested and expected to vest (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Terms Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Terms Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Phase 3 clinical trial initiation - first indication Phase 3 Clinical Trial Initiation - First Indication [Member] Phase 3 Clinical Trial Initiation - First Indication Milestone payments, contingent upon preclinical and clinical trial events (up to) Revenue Recognition, Milestone Method, Contingent Upon Pre Clinical, Regulatory And Commercial Events Revenue Recognition, Milestone Method, Contingent Upon Pre Clinical, Regulatory And Commercial Events Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Aggregate intrinsic value, options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Royalties agreement, maximum annual royalty payout capacity Advance Future Royalties, Annual Sales Threshold Advance Future Royalties, Annual Sales Threshold Aggregate intrinsic value, restricted stock units expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Stock-based compensation APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Short-term investments Debt Securities, Available-for-Sale, Current Settlement agreement rate Advance Future Royalties, Minimum Global Net Sales, Rate Advance Future Royalties, Minimum Global Net Sales, Rate Other Other Accrued Liabilities, Current Milestones that may be recognized in the future Revenue Recognition, Milestone Method, Contingent Revenue Recognition, Milestone Method, Contingent Zejula Royalty Monetization Agreement Zejula Royalty Monetization Agreement [Member] Zejula Royalty Monetization Agreement Description of the Business Nature of Operations [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Royalty and milestone payments Repayment Of Advance Future Royalty And Milestones Repayment Of Advance Future Royalty And Milestones Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Interim President and Chief Executive Officer Interim President And Chief Executive Officer [Member] Interim President And Chief Executive Officer Total stockholders’ equity Stockholders' equity, beginning balance Stockholders' equity, ending balance Equity, Attributable to Parent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Royalty percent on net sales Net Sales Royalty, Percent Net Sales Royalty, Percent Subsequent Events [Abstract] Subsequent Events [Abstract] Mutual funds Mutual Fund [Member] Non-cash interest expense for the sale of future royalties Non-cash interest expense Non-cash interest expense recognized Noncash Advance Future Royalties, Interest Expense Noncash Advance Future Royalties, Interest Expense Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Discovery programs Revenue Recognition, Material Agreement Terms, Programs Revenue Recognition, Material Agreement Terms, Programs Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Stock options outstanding, beginning balance (in dollars per share) Stock options outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Non-cash stock-based compensation cost Share-Based Payment Arrangement, Noncash Expense Investments at fair value Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Common Stock Common Stock [Member] Long-term investments Debt Securities, Available-for-Sale, Noncurrent City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Filing of the first MAA - second indication Filing of MMA - Second Indication [Member] Filing of MMA - Second Indication Document Fiscal Year Focus Document Fiscal Year Focus Schedule of Milestones Achieved Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Lease term Lessee, Operating Lease, Term of Contract Issuance of common stock from exercises of options and employee stock purchase plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options And Employee Stock Purchase Plan Share-based Compensation Arrangement by Share-based Payment Award, Options And Employee Stock Purchase Plan Advance Future Royalties, Payment [Axis] Advance Future Royalties, Payment [Axis] Advance Future Royalties, Payment Minimum Minimum [Member] Amounts accrued for repurchases of common stock Repurchase of Common Stock Incurred But Not Yet Paid Repurchase of Common Stock Incurred But Not Yet Paid Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Phase 3 clinical trial initiation - second indication Phase 3 clinical Trial Initiation - Second Indication [Member] Phase 3 clinical Trial Initiation - Second Indication [Member] Schedule of Activity Related to Stock Option Awards Share-Based Payment Arrangement, Option, Activity [Table Text Block] Receivables from collaborative partners Receivables, Net, Current Area of leased property (sqft) Area of Real Estate Property Receivable related to issuance of common stock, upon exercise of stock options Receivables for Stock Options Exercised Receivables for Stock Options Exercised Comprehensive gain (loss), net Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Advance Future Royalties, Payment [Domain] Advance Future Royalties, Payment [Domain] Advance Future Royalties, Payment [Domain] US Treasury Securities US Treasury Securities [Member] Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Jemperli Royalty Monetization Agreement Jemperli Royalty Monetization Agreement [Member] Jemperli Royalty Monetization Agreement Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Accretion/amortization of investments, net Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders’ equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other income (expense), net: Nonoperating Income (Expense) [Abstract] Other long-term assets Other Assets, Noncurrent Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Basic (in dollars per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Increase in annual rent percentage Annual Rent Increase, Percent Annual Rent Increase, Percent Accounting Policies [Abstract] Accounting Policies [Abstract] Sale of Stock [Domain] Sale of Stock [Domain] 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Schedule of Unrealized Loss and Fair Values in a Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Equity Incentive Plan, 2017 Equity Incentive Plan, 2017 [Member] Equity Incentive Plan, 2017 [Member] Entity Address, City or Town Entity Address, City or Town Liability related to sale of future royalties Advance Future Royalties, Liability, Noncurrent Advance Future Royalties, Liability, Noncurrent Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Basis of Consolidation Consolidation, Policy [Policy Text Block] Capital shares reserved for future issuance, increase (in shares) Common Stock, Capital Shares Reserved For Future Issuance, Increase Common Stock, Capital Shares Reserved For Future Issuance, Increase Amendment Collaboration and Exclusive License Agreement [Member] Collaboration and Exclusive License Agreement Balance Sheet Accounts and Supplemental Disclosures Supplemental Balance Sheet Disclosures [Text Block] Document Transition Report Document Transition Report Liabilities Related To Sale Of Future Royalties [Roll Forward] Liabilities Related To Sale Of Future Royalties [Roll Forward] Liabilities Related To Sale Of Future Royalties Common stock, shares authorized (in shares) Common Stock, Shares Authorized Available-for-sale securities, debt securities Total Fair Value Debt Securities, Available-for-Sale Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Filing of the first MAA - first indication Filing of MMA - First Indication [Member] Filing of MMA - First Indication Other Liabilities Disclosure [Abstract] Employee Stock Purchase Plan, 2017 Employee Stock Purchase Plan, 2017 [Member] Employee Stock Purchase Plan, 2017 [Member] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Title of Individual [Domain] Title of Individual [Domain] AnaptysBio-generated Zejula and Jemperli Zejula and AnaptysBio Generated Jemperli [Member] Zejula and AnaptysBio Generated Jemperli Filing of the first BLA - first indication Filing of Biologics License Application - First Indication [Member] Filing of Biologics License Application - First Indication Noncash advance future royalties revenue Noncash Advance Future Royalties Revenue Noncash Advance Future Royalties Revenue Additional paid in capital Additional Paid in Capital Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Proceeds from stock options exercised Proceeds from Stock Options Exercised Lease termination term Lessee, Operating Lease, Expiration Period Lessee, Operating Lease, Expiration Period Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Forfeitures and cancellations (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Net of proceeds Advance Future Royalties, Liability, Noncurrent, Net Advance Future Royalties, Liability, Noncurrent, Net Royalty Agreement, Up To $1.0 billion Royalty Agreement, Up To $1. 0 billion [Member] Royalty Agreement, Up To $1. 0 billion Aggregate intrinsic value, options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Entity Registrant Name Entity Registrant Name DRI Healthcare Trust DRI Healthcare Trust [Member] DRI Healthcare Trust Second commercial sales milestone Second Commercial Sales Milestone [Member] Second Commercial Sales Milestone Aggregate offering of (up to) Sale of Stock, Authorized Aggregate Offering, Maximum Sale of Stock, Authorized Aggregate Offering, Maximum At any time after 2027 Third Installment [Member] Third Installment Beginning balance Ending balance Advance Future Royalties, Liabilities Advance Future Royalties, Liabilities Document Period End Date Document Period End Date Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Weighted-average exercise price per share, Stock options exercisable, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Repayment of liability for sale of future royalties Royalty and milestone payments to Sagard Advance Future Royalty And Milestone Payments Advance Future Royalty And Milestone Payments Entity Central Index Key Entity Central Index Key Stock based compensation expense Share-Based Payment Arrangement, Expense Upfront license fee received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Weighted average remaining contractual term, other than options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Accrued compensation and related expenses Employee-related Liabilities, Current Fair Value Measurements and Available for Sale Investments Fair Value Disclosures [Text Block] Effective interest rate Advance Future Royalties, Interest Rate, Effective Percentage Advance Future Royalties, Interest Rate, Effective Percentage Fourth commercial sales milestone Fourth Commercial Sales Milestone [Member] Fourth Commercial Sales Milestone Issuance costs related to the sale of future royalties Advance Future Royalties, Issuance Costs Advance Future Royalties, Issuance Costs 12 months or greater, Gross unrealized losses Unrealized losses on available for sale investments in unrealized loss position for greater than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Equity [Abstract] Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Amendment Flag Amendment Flag Money market funds Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Less than 12 months, Gross unrealized losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Repurchases and retirements of common stock (in shares) Stock Repurchased and Retired During Period, Shares Total number of shares purchased (in shares) Treasury Stock, Shares, Acquired During 2027 Second Installment [Member] Second Installment Amounts accrued for issuance costs related to the sale of future royalties Noncash Advance Future Royalties, Issuance Costs, Incurred but Not yet Paid Noncash Advance Future Royalties, Issuance Costs, Incurred but Not yet Paid Leasehold improvements Leasehold Improvements [Member] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Anti-TIM-3 (GSK4069889A/Cobolimab) AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) [Member] AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) Former CEO Former Chief Executive Officer [Member] Former Chief Executive Officer Schedule of Royalty Transaction Activity Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Operating expenses: Operating Expenses [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Additional Paid-in Capital Additional Paid-in Capital [Member] Total assets Assets Cover [Abstract] Cover [Abstract] Subsequent Events Subsequent Events [Text Block] Recurring Fair Value, Recurring [Member] Amortization of issuance costs Amortization Of Advance Future Royalties Issuance Costs Amortization Of Advance Future Royalties Issuance Costs Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Total minimum payments required Lessee, Operating Lease, Liability, to be Paid Forfeitures and cancellations (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Third commercial sales milestone Third Commercial Sales Milestone [Member] Third Commercial Sales Milestone Total operating expenses Operating Expenses Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Lease renewal term Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Loss from operations Operating Income (Loss) Milestones recognized through September 30, 2023 Cumulative Milestones Recognized [Member] Cumulative Milestones Recognized Office furniture and equipment Office Equipment [Member] Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Statement [Line Items] Statement [Line Items] First commercial sales milestone First Commercial Sales Milestone [Member] First Commercial Sales Milestone Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Non-cash interest expense and amortization of issuance costs Noncash Advance Future Royalties And Amortization Of Advance Future Royalties, Interest Expense Noncash Advance Future Royalties And Amortization Of Advance Future Royalties, Interest Expense Name of Property [Axis] Name of Property [Axis] Initiated in vivo toxicology studies using good laboratory practices (GLPs) In Vivo Toxicology Studies [Member] In Vivo Toxicology Studies [Member] Collaboration Revenue [Member] Collaboration Revenue